All In Biotech

Drug Trial Radar · NCT01345669

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Dec 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 617 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

617

Actual

Start

Oct 17, 2011

Primary completion

Sep 12, 2016

Study completion Sep 12, 2016

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomised, double-blind phase III trial will be performed in patients with head and neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy and safety of afatinib (BIBW 2992) with placebo as adjuvant therapy to patients who have received definitive chemo-radiotherapy.

Conditions

  • Head and Neck Neoplasms

Interventions

  • PlaceboDrug

    Once daily

  • AfatinibDrug

    Once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS)Time frame: Up to 5 years

Locations

162 sites in 29 countries. Site status is shown where the registry gives one.

  • 1200.131.00171 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1200.131.00181 Boehringer Ingelheim Investigational Site

    Orange, California

  • 1200.131.00177 Boehringer Ingelheim Investigational Site

    Aurora, Colorado

  • 1200.131.00185 Boehringer Ingelheim Investigational Site

    New Haven, Connecticut

  • 1200.131.00173 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1200.131.00176 Boehringer Ingelheim Investigational Site

    Boston, Massachusetts

  • 1200.131.00182 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 1200.131.00175 Boehringer Ingelheim Investigational Site

    Lebanon, New Hampshire

  • 1200.131.00179 Boehringer Ingelheim Investigational Site

    Stony Brook, New York

  • 1200.131.00188 Boehringer Ingelheim Investigational Site

    The Bronx, New York

  • 1200.131.10200 Boehringer Ingelheim Investigational Site

    Winston-Salem, North Carolina

  • 1200.131.00172 Boehringer Ingelheim Investigational Site

    Philadelphia, Pennsylvania

  • 1200.131.00184 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 1200.131.00198 Boehringer Ingelheim Investigational Site

    Spokane Valley, Washington

  • 1200.131.00183 Boehringer Ingelheim Investigational Site

    Wenatchee, Washington

  • 1200.131.05451 Boehringer Ingelheim Investigational Site

    Ciudad Autonoma de Bs As, Argentina

  • 1200.131.05457 Boehringer Ingelheim Investigational Site

    Córdoba, Argentina

  • 1200.131.05458 Boehringer Ingelheim Investigational Site

    San Miguel de Tucumán, Argentina

  • 1200.131.05452 Boehringer Ingelheim Investigational Site

    Santa Fe, Argentina

  • 1200.131.05453 Boehringer Ingelheim Investigational Site

    Villa Domínico, Argentina

  • 1200.131.06151 Boehringer Ingelheim Investigational Site

    Wooloongabba, Queensland, Australia

  • 1200.131.04353 Boehringer Ingelheim Investigational Site

    Leoben, Austria

  • 1200.131.04357 Boehringer Ingelheim Investigational Site

    Linz, Austria

  • 1200.131.04355 Boehringer Ingelheim Investigational Site

    Salzburg, Austria

  • 1200.131.04351 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1200.131.04359 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1200.131.03259 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1200.131.03256 Boehringer Ingelheim Investigational Site

    Charleroi, Belgium

  • 1200.131.03255 Boehringer Ingelheim Investigational Site

    Hasselt, Belgium

  • 1200.131.03253 Boehringer Ingelheim Investigational Site

    Kortrijk, Belgium

  • 1200.131.03252 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1200.131.03254 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1200.131.03258 Boehringer Ingelheim Investigational Site

    Namur, Belgium

  • 1200.131.05554 Boehringer Ingelheim Investigational Site

    Barretos, Brazil

  • 1200.131.05555 Boehringer Ingelheim Investigational Site

    Jaú, Brazil

  • 1200.131.05557 Boehringer Ingelheim Investigational Site

    Passo Fundo, Brazil

  • 1200.131.05553 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 1200.131.05551 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1200.131.05556 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1200.131.00152 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.